Intranasal Insulin

Off-label use of regular human insulin (Humulin R, NovoLog) delivered via specialized intranasal atomizer to reach brain insulin receptors directly via the olfactory/trigeminal pathway — without systemic absorption, without hypoglycemia. Strongest evidence is in MCI/AD (Craft 2012, modest but real cognitive benefit) and healthy adults for memory + mood (Benedict, Hallschmid lab). The big SNIFF 2020 trial missed primary endpoint primarily because the delivery device was changed mid-study and the replacement device had different deposition characteristics — not because the mechanism failed. Sourcing for a 20yo healthy biohacker is hard: requires US Rx insulin + research-grade nasal atomizer (Optinose, Kurve VP3, or compounded). For Dylan: WATCH-LIST until APOE status is known and cleaner delivery exists.

Plain English: When you inject insulin, it lowers blood sugar but barely touches the brain (the blood-brain barrier blocks most of it). When you spray insulin deep into the right part of the nose, it travels along the olfactory and trigeminal nerves directly into the brain — reaching the hippocampus and other memory regions in 15-30 minutes. Brain insulin doesn't lower blood sugar; it tells neurons to use glucose more efficiently, makes synapses stronger, regulates mood, and dampens food-reward signaling. The trick is that the dose reaching brain via this pathway is so small (microliters of deposition) that systemic absorption is negligible, so blood sugar barely moves.

Detailed mechanism:

1. Nose-to-brain transport pathways — Two parallel routes from the nasal cavity to CNS:

   • Olfactory pathway: Insulin deposits on olfactory epithelium in the cribriform plate region (superior nasal cavity). Crosses the olfactory mucosa via paracellular transport and intracellular axonal transport along olfactory neurons. Reaches olfactory bulb, then spreads to limbic/cortical regions.
   • Trigeminal pathway: Insulin reaches branches of the trigeminal nerve innervating respiratory epithelium. Transport along trigeminal axons reaches brainstem and rostral brain regions.
   • Both pathways bypass the blood-brain barrier entirely. Tmax in CSF is 15-30 minutes after IN dose.

2. Brain insulin receptors — Densely expressed in:

   • Hippocampus: memory consolidation, spatial navigation
   • Hypothalamus: appetite, energy homeostasis, food-reward modulation
   • Prefrontal cortex: executive function, working memory
   • Olfactory bulb: odor processing
   • Amygdala: emotional valence, fear memory
   • Striatum: reward processing

3. Downstream signaling — Insulin receptor activation triggers:

   • PI3K/Akt cascade: synaptic plasticity, anti-apoptotic signaling, GSK3β inhibition
   • MAPK/ERK cascade: long-term potentiation, learning-related gene transcription
   • mTOR activation: protein synthesis at synapses, translation of plasticity-related mRNAs
   • GLUT4 translocation in neurons: improved neuronal glucose uptake (less prominent than in muscle/fat but real)

4. Specific cognitive effects:

   • Declarative memory consolidation (hippocampal): Benedict 2004 — improved word-list recall in healthy young men after 8 weeks of IN insulin
   • Working memory (PFC): Reger 2008 — improved digit span in MCI and APOE4-negative healthy adults
   • Mood + cortisol dampening: IN insulin reduces HPA-axis reactivity to stress; mood improvements reported in multiple healthy-adult trials
   • Food-reward modulation: Hallschmid 2012 — IN insulin reduces palatability ratings of high-calorie food images and reduces ad-libitum intake (mild effect, women > men, lean > obese)
   • Reduced cerebral hypometabolism in AD: FDG-PET signal improvements in Craft 2012 trial

5. Why no hypoglycemia at therapeutic IN dose:

   • 20-40 IU IN dose deposits ~100-500 microliters of insulin solution on nasal mucosa
   • Only a small fraction (estimated <5%) reaches systemic circulation via vascular absorption from nasal mucosa
   • Net systemic dose is sub-physiological (often <2 IU equivalent), well below the threshold for meaningful glycemic effect
   • Transient mild blood glucose drop sometimes detected at 15-30 min post-dose (typically <10 mg/dL), no clinical hypoglycemia in published trials at standard nootropic doses
   • This is the "cleanest" feature of the intervention — direct CNS effect without endocrine cost

6. APOE4 interaction (important):

   • APOE4 carriers in Reger 2008 and Craft 2012 showed different and sometimes opposite response patterns vs APOE4 non-carriers
   • In Craft 2012, APOE4-negative MCI/AD subjects showed clearer cognitive benefit; APOE4-positive subjects showed weaker or null response in some endpoints
   • In healthy young adults, APOE4 carriers showed stronger acute memory enhancement in some Reger work
   • Implication for Dylan: 23andMe APOE genotype (rs429358 + rs7412) directly affects predicted response. Don't act before knowing.

7. Insulin resistance / brain insulin resistance hypothesis:

   • "Type 3 diabetes" framing of AD posits brain insulin resistance as core pathophysiology
   • IN insulin proposed to overcome this resistance via direct receptor stimulation
   • In healthy 20yo with no metabolic disease, this rationale is weaker — Dylan's brain insulin signaling is presumed normal, so headroom for benefit is smaller than in MCI

Pharmacokinetics:

• Onset: 15-30 minutes for measurable CSF/brain effect
• Peak CSF concentration: 30-60 minutes
• Duration of CNS effect: 60-90 minutes acute; effects on memory consolidation persist for hours to days post-dose given action on plasticity
• Systemic absorption: Tiny — peak plasma insulin <2-5 μU/mL above baseline; transient and clinically insignificant in non-diabetic users
• Dose-response: Acute cognitive effects reported at 20-40 IU; chronic trials use 20 IU 1-2× daily up to 4 months; SNIFF used 40 IU 1× daily